Publications
460 publications
- Date
- Relevance
-
GVS advice dapagliflozin (Forxiga®) extension of List 2 conditions
The National Health Care Institute has assessed whether the reimbursement conditions for dapagliflozin (Forxiga®) can be ...
-
Advice on the clustering of combination products and ghost clusters in GVS (part 2)
The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...
-
Package advice lenvatinib (Kisplix®) in combination with pembrolizumab for the treatment of renal cell carcinoma
The National Health Care Institute has assessed whether the medicinal product lenvatinib (Kisplix®) in combination with ...
-
GVS advice on the re-assessment of vericiguat (Verquvo®) for the treatment of adults with chronic heart failure
The National Health Care Institute has assessed whether the medicinal product vericiguat (Verquvo®) can be included in the ...
-
Advisory report on possible candidate for conditional inclusion of atidarsagene autotemcel (Libmeldy®)
The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate atidarsagene autotemcel ...
-
Evaluation of orphan drugs arrangement eculizumab (Soliris®) for the treatment of atypical Haemolytic Uraemic Syndrome (aHUS)
The National Health Care Institute concludes that agreements made in 2016 about the use of the medicinal product eculizumab ...
-
GVS advice on lanadelumab (Takhzyro®) for the prevention of recurrent attacks of hereditary angioedema (HAE)
The National Health Care Institute has assessed whether the medicinal product lanadelumab (Takhzyro®) can be included in the ...
-
GVS advice on sacubitril/valsartan (Entresto®)
At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute has carried out an ...
-
Package advice on the lock procedure medicinal product brexucabtagene autoleucel (Tecartus®) for the treatment of mantle cell lymphoma (MCL)
The National Health Care Institute has assessed whether the medicinal product brexucabtagene autoleucel (Tecartus®) can be ...
-
GVS advice for the extension of the List 2 conditions for evolocumab (Repatha®) and alirocumab (Praluent®) for excessively high cholesterol
The National Health Care Institute has assessed whether the PCSK9 inhibitors evolocumab (Repatha®) and alirocumab (Praluent®) can ...